long-acting beta2-agonist
PreclinicalSmall molecule
Novartislong-acting beta2-agonist is one of 6 small molecule programs targeting Glucocorticoid. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Glucocorticoid
#DrugCompanyPhaseTrials
1Mifeprex
DDanco
Approved
Pulmicort
SSalix
Approved
Enbrel
IImmunex
Phase 1
Prednison
NovartisPreclinical
Long-Acting Muscarinic Antagonists(lama)
Boehringer IngelheimPreclinical
long-acting beta2-agonist
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Glucocorticoid1 trial
Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD
Completed·—·N/A·NCT02147015·248 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for long-acting beta2-agonist. EMBL-EBI & Wellcome Sanger Institute.
- [4]